With re­lo­ca­tion vote loom­ing, the EMA is open­ly fret­ting as cities jock­ey for at­ten­tion

The biggest de­ci­sion that the EMA faces has noth­ing to do with any drug an­gling for a Eu­ro­pean ap­proval or how it’s do­ing rel­a­tive to the FDA in pro­vid­ing ef­fi­cient prod­uct re­views. In 10 days the EU will vote on which of the 19 prospec­tive cities will win the right to host the agency in one of the most hot­ly con­test­ed com­pe­ti­tions to come out of the UK’s vote in fa­vor of Brex­it.

The win­ner will im­me­di­ate­ly get the full at­ten­tion of the lead­ers of the EMA, who have a list of de­mands ready to go.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.